FDA rejects Xarelto for preventing stent thrombosis in ACS

06/30/2013 | Forbes · Bloomberg · Healio

The FDA rejected a request from Johnson & Johnson and Bayer AG to expand the use of their blood thinner rivaroxaban, or Xarelto, to prevent stent thrombosis in patients with acute coronary syndrome. The FDA has asked J&J's Jannsen Pharmaceuticals for more information about the drug's use in ACS patients. The agency previously declined a supplemental new drug application for general use of the drug to treat ACS.

View Full Article in:

Forbes · Bloomberg · Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX